CCL5 and breast carcinoma: TCGA (The Cancer Genome Atlas) data show that 4% of breast tumours have CCL5 dysregulation (2% in basal tumours), mainly related to genetic downregulation which has been previously associated with breast cancer progression.22CCL5 expressed by tumours recruits tumour infiltrant lymphocytes (TILs).